The total return over the past 12 months is +7.45% vs. +16.94% for the S&P 500. So far it's up +37.92% this year. Includes price appreciation + reinvested dividends.
| Category | 1Y (TTM) | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Price CAGR | +7.45% | +17.90% | +2.45% | N/A | N/A | N/A |
| Total Return CAGR | +7.45% | +17.90% | +2.45% | N/A | N/A | N/A |
| Revenue CAGR | +77.83% | +108.43% | +222.46% | N/A | N/A | N/A |
| Net Income CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| EPS CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Cash Flow CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Dividends CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
Visualize historical growth rates over rolling horizons. Use the dropdown to select different metric vectors.
Fennec Pharmaceuticals Inc. (FENC)
| Year | Start price | End price | FENC Return | SPY Return | Outperformance |
|---|---|---|---|---|---|
| 2026(YTD) | $7.70 | $10.62 | +37.92% | +14.51% | +23.41% |
| 2025 | $6.32 | $7.70 | +21.84% | +17.72% | +4.12% |
| 2024 | $11.22 | $6.32 | (43.67%) | +24.89% | (68.56%) |
| 2023 | $9.60 | $11.22 | +16.88% | +26.19% | (9.31%) |
| 2022 | $4.40 | $9.60 | +118.18% | (18.17%) | +136.35% |
| 2021 | $7.45 | $4.40 | (40.94%) | +28.74% | (69.68%) |
| 2020 | $6.49 | $7.45 | +14.79% | +18.37% | (3.58%) |
| 2019 | $6.38 | $6.49 | +1.72% | +31.22% | (29.50%) |
| 2018 | $10.02 | $6.38 | (36.33%) | (4.56%) | (31.77%) |
Start and end prices are split-adjusted closing prices. Total return includes reinvested dividends, so it can differ from the price change.
